Cargando…
SAT-502 Bisphosphonates for Treatment of Calcitriol-Induced Hypercalcemia
Calcitriol excess is a less common cause of hypercalcemia than hyperparathyroidism. While its primary mechanism is thought to be increased intestinal calcium absorption, accelerated bone resorption contributes as well. The mechanism is presumably through a molecular interaction between the receptor...
Autores principales: | Mateo, Roselyn Cristelle, Ortiz, Ricardo, Rosen, Harold |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551686/ http://dx.doi.org/10.1210/js.2019-SAT-502 |
Ejemplares similares
-
SAT-346 Hypercalcemia Secondary to Calcitriol and PTHrP Cosecretion Only Responsive to Hydroxychloroquine
por: Panvelker, Samir S, et al.
Publicado: (2020) -
SAT259 A Rare Case Of Bisphosphonate Refractory Hypercalcemia; Cancer Masquerading As Hidradenitis Suppurativa
por: Robles, Lydia A, et al.
Publicado: (2023) -
SAT-345 Etanercept Induced Hypercalcemia
por: Chaker, Bayan, et al.
Publicado: (2020) -
SAT-499 Denosumab for Treatment of Hypercalcemia in Myelofibrosis
por: Wong, Beatrice, et al.
Publicado: (2019) -
Calcitriol-Mediated Hypercalcemia from Hepatic Granulomatosis Following Percutaneous Cholecystostomy Tube
por: Cater, Taylor, et al.
Publicado: (2021)